{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:38:30Z","timestamp":1794641910356,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["Sanofi Genzyme"],"award-info":[{"award-number":["Sanofi Genzyme"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background:<\/jats:title>\n                <jats:p>Infantile-onset Pompe disease (IOPD) is a rare and devastating, autosomal recessive lysosomal storage disorder that manifests immediately after birth. In severe IOPD cases, complete\/almost-complete acid alpha-glucosidase enzyme deficiency is observed. Considering the rapid progression of the disease, timely diagnosis and treatment are important; even slight delays can remarkably alter the course of the disease. Enzyme replacement therapy (ERT) with recombinant human acid alpha-glucosidase is safe and beneficial for IOPD patients. However, there is heterogeneity in the patient response to ERT. The factors influencing treatment effectiveness include the patient\u2019s age at the time of treatment initiation, pre-existing muscle damage, and cross-reactive immunologic material (CRIM) status at baseline. Immunomodulation along with ERT is the recently developed therapeutic approach that has been included in the therapeutic armamentarium of IOPD for optimizing clinical benefits, particularly in CRIM-negative IOPD patients. However, there is a dearth of published data on the early diagnosis and clinical position of the immunomodulation protocol along with ERT in the treatment of IOPD in the Gulf region.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results:<\/jats:title>\n                <jats:p>Expert panel meetings, involving six experts from the Kingdom of Saudi Arabia, Kuwait, Oman, Qatar, and the United Arab Emirates, were convened to develop consensus-based recommendations addressing current diagnostic and management challenges for patients with IOPD in the Gulf region. Furthermore, this consensus guideline may be implemented in clinical practice for the timely diagnosis and management of patients with IOPD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion:<\/jats:title>\n                <jats:p>The expert consensus will help clinicians to make appropriate and timely decisions regarding immunomodulation initiation and ERT treatment in IOPD patients in the Gulf region.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02545-w","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T19:07:56Z","timestamp":1666897676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Expert Group Consensus on early diagnosis and management of infantile-onset pompe disease in the Gulf Region"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7173-2044","authenticated-orcid":false,"given":"Zuhair","family":"Al-Hassnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia Al","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawal","family":"Makhseed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawfeg Ben","family":"Omran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Al Jasmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal Al","family":"Teneiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"2545_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ymgmr.2018.02.001","volume":"15","author":"ZN Al-Hassnan","year":"2018","unstructured":"Al-Hassnan ZN, Khalifa OA, Bubshait DK, Tulbah S, Alkorashy M, Alzaidan H, et al. The phenotype, genotype, and outcome of infantile-onset Pompe disease in 18 Saudi patients. Mol Genet Metab Rep. 2018;15:50\u20134. https:\/\/doi.org\/10.1016\/j.ymgmr.2018.02.001.","journal-title":"Mol Genet Metab Rep"},{"issue":"4","key":"2545_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.5546\/aap.2019.eng.271","volume":"117","author":"LB Bay","year":"2019","unstructured":"Bay LB, Denzler I, Durand C, Eiroa H, Frabasil J, Fainboim A, et al. Infantile-onset Pompe disease: Diagnosis and management. Arch Argent Pediatr. 2019;117(4):271\u20138. https:\/\/doi.org\/10.5546\/aap.2019.eng.271.","journal-title":"Arch Argent Pediatr"},{"key":"2545_CR3","doi-asserted-by":"publisher","first-page":"100591","DOI":"10.1016\/j.ymgmr.2020.100591","volume":"23","author":"YH Chien","year":"2020","unstructured":"Chien YH, Tsai WH, Chang CL, Chiu PC, Chou YY, Tsai FJ, et al. Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences. Mol Genet Metab Rep. 2020;23:100591. https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100591.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"2545_CR4","doi-asserted-by":"publisher","first-page":"e000182","DOI":"10.1136\/bmjpo-2017-000182","volume":"2","author":"N Elenga","year":"2018","unstructured":"Elenga N, Verloes A, Mrsic Y, Basurko C, Schaub R, Cuadro-Alvarez E, et al. Incidence of infantile Pompe disease in the Maroon population of French Guiana. BMJ Paediatr Open. 2018;2(1):e000182. https:\/\/doi.org\/10.1136\/bmjpo-2017-000182.","journal-title":"BMJ Paediatr Open"},{"key":"2545_CR5","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.ncl.2014.04.010","volume":"32","author":"M Dasouki","year":"2014","unstructured":"Dasouki M, Jawdat O, Almadhoun O, Pasnoor M, McVey AL, Abuzinadah A, et al. Pompe disease: Literature review and case series. Neurol Clin. 2014;32:751\u20139. https:\/\/doi.org\/10.1016\/j.ncl.2014.04.010.","journal-title":"Neurol Clin"},{"key":"2545_CR6","doi-asserted-by":"publisher","first-page":"e9186","DOI":"10.1097\/MD.0000000000009186","volume":"96","author":"M Mart\u00ednez","year":"2017","unstructured":"Mart\u00ednez M, Romero MG, Guereta LG, Cabrera M, Regojo RM, Albajara L, et al. Infantile-onset Pompe disease with neonatal debut: A case report and literature review. Med (Baltim). 2017;96:e9186. https:\/\/doi.org\/10.1097\/MD.0000000000009186.","journal-title":"Med (Baltim)"},{"key":"2545_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3892\/etm.2015.2862","volume":"11","author":"Y Liu","year":"2016","unstructured":"Liu Y, Yang Y, Wang B, Wu L, Liang H, Kan Q, et al. Infantile Pompe disease: A case report and review of the Chinese literature. Exp Ther Med. 2016;11:235\u20138. https:\/\/doi.org\/10.3892\/etm.2015.2862.","journal-title":"Exp Ther Med"},{"key":"2545_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/8904_2012_182","volume":"10","author":"FA Al-Jasmi","year":"2013","unstructured":"Al-Jasmi FA, Tawfig N, Berniah A, Ali BR, Taleb M, Hertecant JL, et al. Prevalence and novel mutations of lysosomal storage disorders in United Arab Emirates: LSD in UAE. JIMD Rep. 2013;10:1\u20139. https:\/\/doi.org\/10.1007\/8904_2012_182.","journal-title":"JIMD Rep"},{"key":"2545_CR9","first-page":"373","volume":"11","author":"M Mahnashi","year":"2021","unstructured":"Mahnashi M, Alshehri A, Cupler E, Faden M, Malibari O, Hakami A, et al. Diagnosis and management of Pompe disease in Saudi Arabia. Am J Med Med Sci. 2021;11:373\u201381.","journal-title":"Am J Med Med Sci"},{"key":"2545_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/jmd2.12062","volume":"49","author":"FB Lagler","year":"2019","unstructured":"Lagler FB, Moder A, Rohrbach M, Hennermann J, Mengel E, G\u00f6kce S, et al. Extent, impact, and predictors of diagnostic delay in Pompe disease: A combined survey approach to unveil the diagnostic odyssey. JIMD Rep. 2019;49:89\u201395. https:\/\/doi.org\/10.1002\/jmd2.12062.","journal-title":"JIMD Rep"},{"key":"2545_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","volume":"66","author":"PS Kishnani","year":"2009","unstructured":"Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A, Clancy JP, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66:329\u201335. https:\/\/doi.org\/10.1203\/PDR.0b013e3181b24e94.","journal-title":"Pediatr Res"},{"key":"2545_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s10545-010-9206-3","volume":"33","author":"A Chakrapani","year":"2010","unstructured":"Chakrapani A, Vellodi A, Robinson P, Jones S, Wraith JE. Treatment of infantile Pompe disease with alglucosidase alpha: The UK experience. J Inherit Metab Dis. 2010;33:747\u201350. https:\/\/doi.org\/10.1007\/s10545-010-9206-3.","journal-title":"J Inherit Metab Dis"},{"key":"2545_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.21037\/atm.2019.05.27","volume":"7","author":"AK Desai","year":"2019","unstructured":"Desai AK, Li C, Rosenberg AS, Kishnani PS. Immunological challenges and approaches to immunomodulation in Pompe disease: A literature review. Ann Transl Med. 2019;7:285. https:\/\/doi.org\/10.21037\/atm.2019.05.27.","journal-title":"Ann Transl Med"},{"key":"2545_CR14","doi-asserted-by":"publisher","first-page":"e67052","DOI":"10.1371\/journal.pone.0067052","volume":"8","author":"SG Banugaria","year":"2013","unstructured":"Banugaria SG, Prater SN, Patel TT, Dearmey SM, Milleson C, Sheets KB, et al. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: A step towards improving the efficacy of ERT. PLoS ONE. 2013;8:e67052. https:\/\/doi.org\/10.1371\/journal.pone.0067052.","journal-title":"PLoS ONE"},{"key":"2545_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12883-015-0412-3","volume":"15","author":"F Al Jasmi","year":"2015","unstructured":"MENA Pompe Working Group. Al Jasmi F, Al Jumah M, Alqarni F, Al-Sanna\u2019a N, Al-Sharif F, et al. Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: Consensus recommendations from an expert group. BMC Neurol. 2015;15:205. https:\/\/doi.org\/10.1186\/s12883-015-0412-3.","journal-title":"BMC Neurol"},{"key":"2545_CR16","doi-asserted-by":"publisher","unstructured":"Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline [published correction appears in Genet Med. 2006;8(6):382. ACMG Work Group on Management of Pompe Disease [removed]; Case, Laura [corrected to Case, Laura E]]. Genet Med. 2006;8:267\u2013288. https:\/\/doi.org\/10.1097\/01.gim.0000218152.87434.f3.","DOI":"10.1097\/01.gim.0000218152.87434.f3"},{"key":"2545_CR17","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1017\/cjn.2016.37","volume":"43","author":"M Tarnopolsky","year":"2016","unstructured":"Tarnopolsky M, Katzberg H, Petrof BJ, Sirrs S, Sarnat HB, Myers K, et al. Pompe disease: Diagnosis and management. Evidence-based guidelines from a Canadian Expert Panel. Can J Neurol Sci. 2016;43:472\u201385. https:\/\/doi.org\/10.1017\/cjn.2016.37.","journal-title":"Can J Neurol Sci"},{"key":"2545_CR18","first-page":"15","volume":"34","author":"E Gilbert-Barness","year":"2004","unstructured":"Gilbert-Barness E. Review. Metabolic cardiomyopathy and conduction system defects in children. Ann Clin Lab Sci. 2004;34:15\u201334.","journal-title":"Ann Clin Lab Sci"},{"key":"2545_CR19","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/jpc.14070","volume":"54","author":"P Owens","year":"2018","unstructured":"Owens P, Wong M, Bhattacharya K, Ellaway C. Infantile-onset Pompe disease: A case series highlighting early clinical features, spectrum of disease severity and treatment response. J Paediatr Child Health. 2018;54:1255\u201361. https:\/\/doi.org\/10.1111\/jpc.14070.","journal-title":"J Paediatr Child Health"},{"key":"2545_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/ijns6020030","volume":"6","author":"SC Chiang","year":"2020","unstructured":"Chiang SC, Chien YH, Chang KL, Lee NC, Hwu WL. The timely needs for infantile onset Pompe disease newborn screening-practice in Taiwan. Int J Neonatal Screen. 2020;6:30. https:\/\/doi.org\/10.3390\/ijns6020030.","journal-title":"Int J Neonatal Screen"},{"key":"2545_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/ijns6010004","volume":"6","author":"BK Burton","year":"2020","unstructured":"Burton BK, Charrow J, Hoganson GE, Fleischer J, Grange DK, Braddock SR, et al. Newborn screening for Pompe disease in Illinois: Experience with 684,290 infants. Int J Neonatal Screen. 2020;6:4. https:\/\/doi.org\/10.3390\/ijns6010004.","journal-title":"Int J Neonatal Screen"},{"key":"2545_CR22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s10545-007-0660-5","volume":"30","author":"AA Saadallah","year":"2007","unstructured":"Saadallah AA, Rashed MS. Newborn screening: Experiences in the Middle East and North Africa. J Inherit Metab Dis. 2007;30:482\u20139. https:\/\/doi.org\/10.1007\/s10545-007-0660-5.","journal-title":"J Inherit Metab Dis"},{"key":"2545_CR23","doi-asserted-by":"publisher","first-page":"CD011539","DOI":"10.1002\/14651858.CD011539.pub2","volume":"11","author":"M Chen","year":"2017","unstructured":"Chen M, Zhang L, Quan S. Enzyme replacement therapy for infantile-onset Pompe disease. Cochrane Database Syst Rev. 2017;11:CD011539. https:\/\/doi.org\/10.1002\/14651858.CD011539.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2545_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","volume":"39","author":"CM van Gelder","year":"2016","unstructured":"van Gelder CM, Poelman E, Plug I, Hoogeveen-Westerveld M, van der Beek NAME, Reuser AJJ, et al. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: An open-label single-center study. J Inherit Metab Dis. 2016;39:383\u201390. https:\/\/doi.org\/10.1007\/s10545-015-9912-y.","journal-title":"J Inherit Metab Dis"},{"key":"2545_CR25","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41436-019-0738-0","volume":"22","author":"AA Khan","year":"2020","unstructured":"Khan AA, Case LE, Herbert M, DeArmey S, Jones H, Crisp K, et al. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: A clinical study and review of the literature. Genet Med. 2020;22:898\u2013907. https:\/\/doi.org\/10.1038\/s41436-019-0738-0.","journal-title":"Genet Med"},{"key":"2545_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S2352-4642(21)00308-4","volume":"6","author":"IAM Ditters","year":"2022","unstructured":"Ditters IAM, Huidekoper HH, Kruijshaar ME, Rizopoulos D, Hahn A, Mongini TE, et al. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: A multicentre observational cohort study from the European Pompe Consortium. Lancet Child Adolesc Health. 2022;6:28\u201337. https:\/\/doi.org\/10.1016\/S2352-4642(21)00308-4.","journal-title":"Lancet Child Adolesc Health"},{"key":"2545_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99:26\u201333. https:\/\/doi.org\/10.1016\/j.ymgme.2009.08.003.","journal-title":"Mol Genet Metab"},{"key":"2545_CR28","doi-asserted-by":"publisher","DOI":"10.1055\/a-1110-7335","author":"A Hahn","year":"2020","unstructured":"Hahn A, Hennermann JB, Huemer M, Kampmann C, Marquardt T, Mengel E, et al. Diagnosis and care of infants and children with Pompe disease [published online ahead of print, 2020 February 18]. Klin Padiatr. 2020. https:\/\/doi.org\/10.1055\/a-1110-7335. https:\/\/doi.org\/10.1055\/a-1110-7335.","journal-title":"Klin Padiatr"},{"key":"2545_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/gim.2012.110","volume":"15","author":"SG Banugaria","year":"2013","unstructured":"Banugaria SG, Prater SN, McGann JK, Feldman JD, Tannenbaum JA, Bailey C, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: Lessons learned from Pompe disease. Genet Med. 2013;15:123\u201331. https:\/\/doi.org\/10.1038\/gim.2012.110.","journal-title":"Genet Med"},{"key":"2545_CR30","doi-asserted-by":"publisher","first-page":"e94328","DOI":"10.1172\/jci.insight.94328","volume":"2","author":"ZB Kazi","year":"2017","unstructured":"Kazi ZB, Desai AK, Berrier KL, Troxler RB, Wang RY, Abdul-Rahman OA, et al. Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. JCI Insight. 2017;2:e94328. https:\/\/doi.org\/10.1172\/jci.insight.94328.","journal-title":"JCI Insight"},{"key":"2545_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.21037\/atm.2019.04.70","volume":"7","author":"A Hahn","year":"2019","unstructured":"Hahn A, Sch\u00e4nzer A. Long-term outcome and unmet needs in infantile-onset Pompe disease. Ann Transl Med. 2019;7:283. https:\/\/doi.org\/10.21037\/atm.2019.04.70.","journal-title":"Ann Transl Med"},{"key":"2545_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ymgmr.2015.05.004","volume":"4","author":"EO Stenger","year":"2015","unstructured":"Stenger EO, Kazi Z, Lisi E, Gambello MJ, Kishnani P. Immune tolerance strategies in siblings with infantile Pompe disease-advantages for a preemptive approach to high-sustained antibody titers. Mol Genet Metab Rep. 2015;4:30\u20134. https:\/\/doi.org\/10.1016\/j.ymgmr.2015.05.004.","journal-title":"Mol Genet Metab Rep"},{"key":"2545_CR33","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41436-020-01080-y","volume":"23","author":"C Li","year":"2021","unstructured":"Li C, Desai AK, Gupta P, Dempsey K, Bhambhani V, Hopkin RJ, et al. Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: The benefits of early treatment with enzyme replacement therapy and immune tolerance induction. Genet Med. 2021;23:845\u201355. https:\/\/doi.org\/10.1038\/s41436-020-01080-y.","journal-title":"Genet Med"},{"issue":"2","key":"2545_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid [alpha]-glucosidase: Major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99\u2013109. https:\/\/doi.org\/10.1212\/01.wnl.0000251268.41188.04.","journal-title":"Neurology"}],"updated-by":[{"DOI":"10.1186\/s13023-023-02967-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000}}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02545-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02545-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02545-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:05:30Z","timestamp":1700751930000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02545-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2545"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02545-w","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13023-023-02967-0","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]},"assertion":[{"value":"15 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13023-023-02967-0","URL":"https:\/\/doi.org\/10.1186\/s13023-023-02967-0","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have received a personal fee in the form of honoraria for attending the two advisory board meetings conducted by Sanofi Genzyme, but they have not received fees for writing the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"388"}}